Recently, according to the requirements of the Measures for the Identification and Administration of Pilot and Demonstration Units of Patent Work in Shanghai Enterprises and Institutions (H.ZB [2017] No. 62), Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. was recognized as the "pilot enterprise of patent work in Shanghai in 2021" through expert review and other procedures, and after the study and decision of the Municipal Intellectual Property Office and the Municipal Market Supervision Bureau.

*Intercepted from the public list of pilot demonstration units of patent work in Shanghai to be identified in 2021.

The evaluation of the pilot demonstration units of patent work of enterprises and institutions in Shanghai is an important measure taken by the Shanghai Intellectual Property Office to further implement the national and Shanghai intellectual property strategy and improve the quality, protection effect, application efficiency and management level of patents of enterprises and institutions in Shanghai. Scientific and technological innovation is the driving force of enterprise development, and patent construction is a strong support for scientific and technological innovation.

Being identified as a pilot enterprise for patent work shows the recognition and encouragement of the Shanghai Intellectual Property Office for the intellectual property work and independent innovation ability of Luoqi Biology. Since its establishment, Rocky Biology has attached great importance to the protection and layout of intellectual property rights, and has applied for more than 30 domestic and foreign invention patents, of which 12 Chinese invention patents have been authorized; It obtained the intellectual property management system certification in December 2019.

In the future, Rocky Biology will pay more attention to the creation and protection of intellectual property, constantly improve the intellectual property management system, strengthen the transformation of patent achievements, enhance the awareness of patent risk prevention, and escort the company's innovation and development!

About novamab

Luoqi Biology is a high-tech enterprise dedicated to the research and development of innovative nano antibody drugs. The company was established in Shanghai International Medical Park, with a R&D and production base of more than 2500 square meters and a unique camel breeding base. Luoqi Biological has independently created five core technology platforms based on nano-antibody: nano-antibody rapid screening platform, Pichia pastoris CMC process development platform, inhaled macromolecular drug research and development platform, nano-antibody long-acting platform and nano-antibody dual-antibody platform, all of which have very unique industry advantages. At present, the company is mainly developing products to cover popular targets such as respiration, ophthalmology and cancer, and has developed product research and development strategies for innovative application scenarios to improve drug utilization and patient compliance.